Tradestie Institutional Equity Comparison Engine

MRNA vs VRTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VRTX Overall Edge

VRTX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vertex Pharmaceuticals Inc (VRTX) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus VRTX at 25.9x Forward P/E and 37.8% operating margin (+11.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against VRTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs VRTX 25.9x Fwd P/E
Growth & Margin Winner VRTX
Op Margin -80.8% vs 37.8% ยท YoY +29.2% vs +11.8%
Momentum & Technical Winner MRNA
1Y +706.5% vs +22.3% ยท 52W Pos 67% vs 66%
Options & Structure Winner VRTX
CONSOLIDATION (52nd %ile IV) vs CONSOLIDATION (33rd %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
VRTX NASDAQ
Vertex Pharmaceuticals Inc
Pharmaceutical Preparations
$515.02
-1.08% 1D
Market Cap $132.0B
1M Return -3.77%
1Y Return +22.32%
Forward P/E 25.9x
Unified AI Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 69.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% VRTX +22.32% Spread: +684.13 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue VRTX Revenue MRNA Op. Margin VRTX Op. Margin Margin Edge
FY2018 $140M $3.05B -306.0% 20.8% VRTX
FY2019 $60M $4.16B -906.8% 28.8% VRTX
FY2020 $800M $6.21B -95.0% 46.0% VRTX
FY2021 $18.5B $7.57B 72.0% 36.7% MRNA
FY2022 $19.3B $8.93B 48.9% 48.2% MRNA
FY2023 $6.85B $9.87B -61.9% 38.8% VRTX
FY2024 $3.24B $11.0B -121.9% -2.1% VRTX
FY2025 $1.94B $12.0B -158.1% 34.8% VRTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (4) vs VRTX (6)
Institutional Metric MRNA VRTX Criterion Row Winner
Market Capitalization Scale $80.7B $132.0B Larger Scale VRTX
Trailing P/E Ratio Valuation 23.0x 33.5x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 25.9x Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +11.8% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 37.8% Higher Margin VRTX
Net Profit Margin Profitability -110.5% 30.7% Higher Margin VRTX
Return on Equity (ROE) Capital Efficiency -34.5% 20.8% Higher ROE VRTX
52-Week Range Position Momentum 67% ($22โ€“$281) 66% ($412โ€“$569) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.35ฮฒ ยท 28% Vol Lower Realized Risk VRTX
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 40.9 / 100 (SELL) Higher Composite VRTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs VRTX Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VRTX CONSOLIDATION
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 33rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live VRTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor VRTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.